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ABSTRACT Manypathogensproducethe -(16)-linkedpoly-N-acetylglucosamine(PNAG)surfacepolysaccharidethatisbeing
developedasabroadlyprotectiveantimicrobialvaccine.However,itisunknownwhethersystemicallyinjectedPNAGvaccines
orantibodieswouldprovideprotectiveimmunityagainstpathogensconﬁnedtothegastrointestinaltractsuchasShigatoxin
(Stx)-producing Escherichia coli (STEC), an important group of gastrointestinal (GI) pathogens for which effective immuno-
therapeuticsarelacking.ToascertainwhethersystemicIgGantibodytoPNAGimpactsthisinfectioussituation,avaccinecon-
sistingofasyntheticnonamerofnonacetylatedPNAG,9GlcNH2,conjugatedtotheShigatoxin1bsubunit(9GlcNH2-Stx1b)was
produced. Rabbit antibodies raised to the conjugate vaccine were tested for bacterial killing and toxin neutralization in vitro and
protectionagainstinfectionininfantmice.CellsurfacePNAGwasdetectedonall9STECisolatestested,representing6STEC
serogroups, including E. coli O157:H7. Antibody to the 9GlcNH2-Stx1b conjugate neutralized Stx1 potently and Stx2 modestly.
ForO157:H7andO104:H4STECstrains,antibodieselicitedbythe9GlcNH2-Stx1bconjugatepossessedopsonickillingandbac-
tericidalactivity.Followingintraperitonealinjection,antibodiestobothPNAGandStxwereneededforinfantmouseprotection
againstO157STEC.TheseantibodiesalsomediatedprotectionagainsttheStx2-producingO104:H4strainthatwasthecauseof
arecentoutbreakinGermany,althoughsufﬁcientdosesofantibodytoPNAGalonewereprotectiveagainstthisstrainininfant
mice.OurobservationssuggestthatvaccinationagainstbothPNAGandStx,usingaconstructsuchasthe9GlcNH2-Stx1bconju-
gatevaccine,wouldbeprotectiveagainstabroadrangeofSTECserogroups.
IMPORTANCE Thepresenceofpoly-N-acetylglucosamine(PNAG)onmanypathogenspresentsanopportunitytotargetthisone
structurewithamultispeciesvaccine.WhetherantibodiestoPNAGcanprotectagainstpathogensconﬁnedtothegastrointesti-
nal tract is not known. As Shiga toxin (Stx)-producing Escherichia coli (STEC) bacteria are serious causes of infection whose vir-
ulenceisdependentonelaborationofStx,wepreparedavaccinecontainingasyntheticnonamerofPNAG(9GlcNH2)conju-
gatedtoShigatoxin1bsubunit(9GlcNH2-Stx1b)toevaluatebacterialkilling,toxinneutralization,andprotectiveefﬁcacyin
infantmice.Allnine(100%)clinicalstrainsofSTECfromdifferentserogroupsexpressedPNAG.Vaccine-inducedantibodyme-
diated in vitro killing of STEC and neutralization of both Stx1 and Stx2. Passive administration of antibody to the conjugate
showedprotectionrequiringimmunitytobothPNAGandStxforO157strains,althoughforanO104strain,antibodytoPNAG
alonewasprotective.ImmunitytoPNAGmaycontributetoprotectionagainstSTECinfections.
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O
utbreaksandsporadiccasesofintestinalinfectionscausedby
Shigatoxin(Stx)-producingEscherichiacoli(STEC)havebe-
comeincreasinglycommon(1,2).WhileE.coliO157:H7remains
the most common STEC serogroup (1), additional STEC sero-
groups are being reported more frequently as causes of infection
(2). In 2011, a large outbreak of diarrhea and hemolytic-uremic
syndrome (HUS) caused by a novel Stx-producing strain of sero-
group O104:H4 occurred in Germany (3), and a recent study of
virulence factors of this strain in an infant rabbit model of intes-
tinal colonization and diarrhea indicated that Stx and chromo-
somallyencodedautotransporters,butnottheaggregativeadher-
ence plasmid pAA, were required for disease induction (4). STEC
bacteria are estimated to cause over 265,000 cases of infection
annually in the United States, with more than 3,600 hospitaliza-
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STECrangefromnonbloodydiarrheatohemorrhagiccolitis,and
approximately 5% to 10% of patients with STEC infections de-
velop HUS, a life-threatening complication, with a case fatality
rate of 3% to 5% (6). In the 2011 epidemic in Germany, HUS
developed in 20% of individuals infected with the O104:H4
strain (3, 7).
Shiga toxins are the principal cause of the diarrhea and HUS
associatedwithSTECinfections(8).Theyarecategorizedintotwo
antigenically distinct groups, Stx1 and Stx2, which are potent cy-
totoxins composed of a single toxic A subunit and ﬁve B subunits
(8). Stx2 is more frequently associated with severe disease and is
more potent in toxicity and lethality models in mice (9). Treat-
ment of STEC infection is supportive, and antibiotic use is con-
troversial(10),asithasbeenreportedtopromoteproductionand
release of the phage-encoded Stxs (11, 12) and may increase the
riskofHUS(13).However,notallstudieshavedetectedanimpact
of antibiotic treatment on the development of HUS (14). In light
ofthiscontroversy,vaccinesand/orimmunotherapeuticsthattar-
getShigatoxinsareconsideredavaluableapproachforprevention
and treatment of these common infections.
To date, several Shiga toxin-based vaccine strategies using ei-
ther nontoxic subunits, recombinant proteins, or inactivated ho-
lotoxinshavebeenundertaken(15–17),andseveralprotein-based
vaccineshavebeenshowntoreducefecalsheddingandcarriagein
cows(14).InadditiontoStx,othervaccineantigensthatareunder
development include the lipopolysaccharide (LPS) O-antigens
(e.g., O157) (2, 18) and surface proteins (15); however, the exis-
tence of a variety of STEC O-antigens may limit the utility of the
former approach.
IncontrasttoO-antigens,poly-N-acetylglucosamine(PNAG),
a polymer of -(16)-linked N-acetylglucosamine units, is a
widely conserved carbohydrate that has been detected on the sur-
faceofabroadrangeofpathogensfollowingitsdiscoveryinStaph-
ylococcus epidermidis and Staphylococcus aureus (19, 20). The
highly acetylated glycoform of PNAG naturally expressed on mi-
crobialsurfaceselicitsnonkilling,nonprotectiveantibody(21,22)
due to the antibody’s inability to deposit opsonically active com-
plementontothemicrobialsurface(23).Removalofthemajority
of acetates from the native PNAG molecule (21, 22) or use of a
synthetic oligosaccharide consisting of -(1-6)-linked gluco-
samines(i.e.,noN-linkedacetates)conjugatedtocarrierproteins
(24, 25) generates opsonic or bactericidal antibody protective
against microbes producing the native, highly acetylated PNAG
(24),includingavarietyofE.colistrainsisolatedfromtheurinary
tract (26). However, the evaluation of PNAG-based vaccine can-
didates against STEC or any other pathogen conﬁned to the gas-
trointestinal (GI) tract has not been conducted thus far. To assess
protective potential in the GI tract, a bivalent vaccine was synthe-
sized by conjugating a synthetic -(16)-oligoglucosamine con-
sisting of 9 glucosamine units (nonaglucosamine [9GlcNH2]) to
thecarrierproteinShigatoxin1bsubunit(Stx1b).Stx1bwascho-
sen as opposed to Stx2b, because the latter was reported to be
poorly stable (27) and thus not readily amenable to conjugation.
We found that for O157 STEC strains, antibody induced by the
conjugate vaccine could neutralize both Stx1 and Stx2 and medi-
ate PNAG-speciﬁc opsonic/bactericidal killing. Antibodies to
bothoftheseantigenswererequiredforinvivoprotectionagainst
O157 STEC strains, but antibody to PNAG alone could protect
mice against O104 STEC infection. Since immunity to PNAG can
contribute to resistance to STEC infections in a mouse infection
model, this conserved carbohydrate may be a key component for
development of a broad-spectrum vaccine for STEC.
RESULTS
Detectionofsurface-associatedPNAGinSTEC.Weusedaﬂuo-
rescentlylabeledhumanmonoclonalantibody(MAb)(F598)that
speciﬁcallybindsPNAG(25)andconfocalmicroscopytoassayfor
surface-associated polysaccharide. All four O157:H7 strains ex-
hibited robust staining with F598 and only background staining
with an isotype-matched control human MAb (Fig. 1A). MAb
F598 did not bind to pgaC or pgaABCD derivatives of these 4
strains, which are not capable of PNAG synthesis (Fig. 1A). MAb
F598 binding to cell surfaces of non-O157 STEC strains was ob-
served, and binding was lost after digestion with the PNAG-
degradingenzymedispersinB(28)andPNAG-destroyingsodium
periodate (Fig. 1B). Thus, all 9 STEC strains produce surface-
associated PNAG.
Characterization of the antisera elicited by the 9GlcNH2-
Stx1b conjugate vaccine. The 9GlcNH2-Stx1b conjugate elicited
high-titered IgG antibodies that bound to puriﬁed native PNAG
at levels slightly less than to a reference control raised to
FIG1 Expressionofpoly-N-acetylglucosamine(PNAG)bySTECstrains.(A)
PNAG production by four O157 STEC strains, EDL933, 86-24, 345, and 1144
and their respective pgaC (EDL933) or pgaABCD (other 3 strains) deletion
mutants. (B) PNAG production by non-O157 STEC strains. In panel B, dem-
onstration of speciﬁcity for PNAG was shown by maintenance of MAb F598
binding after treatment with the control enzyme chitinase but loss of binding
after treatment with the PNAG-speciﬁc hydrolytic enzyme dispersin B or re-
actionwithsodiumperiodate,whichhydrolyzesPNAGbybreakingthebonds
between vicinal carbons 3 and 4 that contain hydroxyl groups in
N-acetylglucosamine. The red channel shows DNA, while the green channel
shows control MAb or MAb to PNAG and columns labeled Overlay show
ﬂuorescence in both channels. Green ﬂuorescence that does not overlap red
ﬂuorescence (i.e., strain 345) indicates likely nonspeciﬁc binding of a MAb to
non-cell-associated material. Bars, 10 m.
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Fig. S1A in the supplemental material) (24, 25) and to puriﬁed
Stx1holotoxin(Fig.S1B).Therewasalsoclearlydetectable(albeit
atalowertiter)bindingoftheantibodyraisedtotheStx1bcarrier
to Stx2 (Fig. S1C).
Antisera raised to the 9GlcNH2-Stx1b conjugate mediated op-
sonic killing of PNAG-producing STEC strains in the presence of
the HL-60 phagocytic cells comparable to that of the control im-
mune serum to 9GlcNH2-TT (Fig. 2A and B). In phagocyte-
independent bactericidal killing assays, antibodies to both the
9GlcNH2-TTand9GlcNH2-Stx1bexhibitedbactericidalkillingof
four out of ﬁve STEC strains tested (Fig. 2C and D).
Toxin neutralization assays using a concentration of puriﬁed
native Stx1 (40 pg/ml) that killed ~50% of Vero cells in the ab-
sence of added serum along with twofold serial dilutions of the
antiserumraisedto9GlcNH2-Stx1b,controlnormalrabbitserum
(NRS), or the positive-control MAb to Stx1b revealed a high level
oftoxinneutralizingactivity,withanendpointneutralizationtiter
of ~16,000 (Fig. 2E). The control MAb to Stx1b had detectable
neutralizing activity at a concentration of ~25 ng/ml (Fig. 2E).
FIG2 In vitro opsonophagocytic killing (OPK), bactericidal activity, and Shiga toxin neutralizing activity of the antibodies induced by PNAG-based conjugate
vaccines. (A and B) Opsonophagocytic killing (with HL-60 cells) of the STEC strains indicated on the x axis by antibody in sera raised to 9GlcNH2-TT (A) or
9GlcNH2-Stx1b (B). (C and D) Bactericidal killing (without HL-60 cells) of the STEC strains indicated on the x axis by antibody in sera raised to 9GlcNH2-TT
(C)or9GlcNH2-Stx1b(D).Therewasnokillingintheabsenceofcomplementinanyassay(smallbartotheleftofeach1:10serumdilutionbar).Barsrepresent
means of three replicate samples within an assay. (E and F) Normal rabbit serum (NRS), antibody to the 9GlcNH2-Stx1b conjugate vaccine, MAb to Stx1, or
polyclonal antibody to Stx2 was diluted as indicated on the x axis and mixed with an amount of either Stx1 or Stx2 predetermined to give ~50% killing (dashed
lines)oftheVerocellsin96-wellcultureplates.ThecontrolforStx1neutralizationwasaMAbinitiallyusedat200ng/ml.Thebarsrepresentthecalculatedmean
cell viabilities from six duplicate wells, and the graphs depict a typical experiment representative of 3 repeat assays.
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concentrations tested. Antibody to 9GlcNH2-Stx1b also con-
tained detectable neutralizing activity against Stx2, with an end-
point dilution of 1:320 (Fig. 2F).
Requirements for Stx and PNAG in a lethal, infant mouse-
based STEC infection model. We found we could consistently
achieve a moribund/lethal infection 50 to 120 h postinoculation
followingoralgavageof5-day-oldCD1micewith5108CFU/
mouse of various STEC. Following oral gavage, we sacriﬁced ani-
mals0.25,3,30,and50hpostgavageandmeasuredtheSTECCFU
in the stomachs, small intestines, large intestines, and systemic
tissues,includingthelivers,kidneys,andspleens(seeFig.S2inthe
supplemental material). Within 15 min of infection, STEC bacte-
ria were detected in the stomach, small intestine, and large intes-
tine, where they remained until at least 50 h. STEC CFU in the
stomach and small intestine declined during this period, but high
levelspersistedwithinthelargeintestine(Fig.S2).Nomajorpath-
ological changes were observed in the GI tracts or kidneys by he-
matoxylin and eosin staining of tissue sections after 72 to 96 h of
infection.STECwasnotrecoveredfromanyextraintestinaltissues
at this point (Fig. S2).
We deleted the complete stx1 and stx2 genes in E. coli O157:H7
strainEDL933totestwhethereitheroftheShigatoxinsisrequired
forlethality.Allisogenicmutantstrainshadinvitrogrowthcurves
identical to that of the wild-type (WT) parent, and PCR analysis,
along with detection of toxin expression in vitro, conﬁrmed that
allmutantsretainedorlosttheintendedgenesandcorresponding
protein production. Deletion of stx1 had no effect on EDL933
virulence, whereas EDL933 lacking stx2 did not cause death in
mice, even at doses up to 1010 CFU/animal (Fig. 3A), indicating
that mortality depends on production of lethal amounts of Stx2.
The much greater potency of Stx2 over Stx1 in mice has been
reported previously by others (29, 30). A pgaC EDL933 strain
thatdoesnotproducePNAG(Fig.1)wasavirulent,andnodeaths
were observed (Fig. 3B), similar to the stx2 mutant.
DeletionoftheentirepgalocusinE.colistrains86-24andE345
alsoattenuatedthevirulenceofthese2STECstrains,althoughnot
to the same extent as in EDL933 (Fig. 3C and D). Together, these
observationssuggestthatPNAGcontributestoSTECpathogenic-
ity in this infant mouse model.
Protective efﬁcacy of antiserum raised to 9GlcNH2-Stx1b to
STEC infection. Five-day-old mice were given intraperitoneal
(i.p.) injections of 80 l of the rabbit antiserum raised to the
9GlcNH2-Stx1b conjugate vaccine 16 and 4 h prior to oral infec-
tion (Fig. 4). All mice pretreated with the control NRS became
moribundordiedwithin76hofSTECinoculation,whereas60to
80% mice pretreated with the antisera from the PNAG-Stx1b im-
mune rabbits were alive 120 h after STEC inoculation, including
mice infected with strains lacking the Stx1 target antigen. Three
additional experiments with infant mice challenged with strain
EDL933alsoshowedefﬁcacyrangingfrom50to100%protection
in the immune mice (see Fig. S3 in the supplemental material).
The variability in protective efﬁcacy likely reﬂects the use of out-
bredCD1miceandinabilitytopreciselycontrolsomeexperimen-
tal factors such as the exact inoculum size, comparability of chal-
lenge inocula prepared on different days, and factors that
naturally vary within an animal’s environment. Nonetheless, im-
munization with the 9GlcNH2-Stx1b conjugate vaccine elicited
protective antibodies against lethal STEC infection as demon-
strated in multiple experiments.
Antibodies to either PNAG or Stx present in the antisera elic-
itedbythe9GlcNH2-Stx1bvaccinecouldindividuallyconferpro-
FIG 3 Virulence of stx and pga mutants of E. coli O157 strains orally gavaged into 5-day-old mice. (A) Deletion of the stx2 gene, but not the stx1 gene, resulted
in complete loss of virulence for E. coli EDL933. The challenge doses (in CFU) are indicated on the graphs, and the numbers in the parentheses are the number
of survivors to the total number of infected mice. (B to D) Loss of ability to produce PNAG by deletion of the pgaC gene in strain EDL933 (B) or the entire pga
locus(strains86-24[C]andE345[D])decreasesvirulenceofthesethreeE.coliO157strainsininfantmice.Pvaluesweredeterminedbylogranktestscomparing
the values for the wild-type (WT) E. coli with the values for mutant strains.
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for full efﬁcacy. We thus compared protective efﬁcacy of the anti-
seraraisedto9GlcNH2-Stx1bwithahigh-titeredantiseraraisedto
9GlcNH2-TT, which has only antibody to PNAG (24). The latter
antiserum had no protective efﬁcacy in mice (Fig. 5A), even if 3
doses were given starting 16 h preinfection and at 24 and 48 h
postinfection. Addition of a monoclonal antibody to Stx1 to the
monospeciﬁc antiserum to PNAG also did not result in any pro-
tection (Fig. 5A). Furthermore, antibody to PNAG alone had no
protective efﬁcacy against EDL933 stx1 and 86-24, STEC strains
that produce only Stx2 (Fig. 5B and C). Using absorption experi-
ments, we found that absorption of the antibody to PNAG from
the serum raised to 9GlcNH2-Stx1b (anti-9GlcNH2-Stx1b ab-
sorbed) removed detectable antibody to this antigen and also ab-
rogated protection (Fig. 5B and C). Restoration of protection was
achieved by addition to the anti-9GlcNH2-Stx1b absorbed serum
of antibody raised to 9GlcNH2-TT (Fig. 5B and C). Thus, in this
model, neither antibody to Stx1b alone or PNAG alone was pro-
tective, but together they could prevent an otherwise lethal infec-
tion. Since antibody to Stx1b was essential to the protection of
infantmicechallengedwithstrainsproducingonlyStx2,ourﬁnd-
ings also suggest that the titer of antibody to Stx2 elicited by the
Stx1b carrier protein was sufﬁcient to mediate this protection,
consistent with a prior report on cross-reactivity of some murine
MAbs to both Shiga toxins (31).
Protection against Stx-producing E. coli O104:H4. We next
tested whether antibodies to PNAG with or without antibody to
Stx protected mice against lethal oral infection with enteroaggre-
gativeE.coli(EAEC)O104:H4.Wei.p.injectedtwoorthreedoses
of the antiserum containing antibody only to PNAG (anti-
9GlcNH2-TT) or twice with the antiserum raised against
9GlcNH2-Stx1b. Two injections of serum with antibody to both
PNAG and Stx1b protected infant mice against EAEC O104:H4
infection, whereas two injections of antibody to PNAG signiﬁ-
cantly (P  0.04) extended survival, but ﬁnal mortality was the
same as in mice given NRS (Fig. 5E). However, three doses of
antiserum containing only antibody to PNAG administered 16 h
prior to infection as well as 24 and 48 h postinfection was protec-
tive against lethality caused by the E. coli O104 strain (Fig. 5F).
Protection against non-Stx-producing E. coli. To assess
whether antibody raised to the 9GlcNH2-Stx1b conjugate could
protect against a non-Stx-producing, PNAG-positive E. coli iso-
late as previously shown for antibody raised to the 9GlcNH2-TT
conjugate(24),adultmiceweregiven0.2mlofantisera24hprior
to i.p. infection with 1.5  108 CFU of E. coli urinary tract infec-
tion (UTI) strain J and sacriﬁced 48 h later when the bacterial
levelsintheliversweredetermined(seeFig.S4inthesupplemen-
tal material). This antiserum signiﬁcantly (P  0.03 [Fig. S4])
loweredbacteriallevelscomparedwithmicegivenNRS,and5of8
oftheimmuneanimalshadsterileliversasopposedto1of8mice
given NRS (P  0.059 by one-tailed Fisher’s exact test). Thus, the
9GlcNH2 oligosaccharide conjugated to TT (24) or Stx1b elicited
comparable,broadlyreactive,andprotectiveantibodytothecon-
served PNAG antigen.
DISCUSSION
In this study, we evaluated the ability of antibody raised to a sys-
temically delivered conjugate of a glucosamine nonasaccharide,
9GlcNH2,andStx1btomediateinvitrobacterialkilling,Stxholo-
toxin neutralization, and in vivo protection against STEC. We
demonstrated that cell surface-associated PNAG was detected in
all 9 STEC isolates representing 6 STEC serogroups that we tested
andfoundthatantibodytothe9GlcNH2-Stx1bconjugateneutral-
ized Stx1 potently and Stx2 modestly. For the O157 STEC strains,
FIG 4 Protective efﬁcacy of antibody raised to the 9GlcNH2-Stx1b synthetic oligosaccharide-conjugate vaccine against three O157:H7 STEC strains. Kaplan-
MeiersurvivalcurvesanalyzedbythelogranktestwereusedtogeneratetheindicatedPvalues.Thenumbersinparenthesesarethenumbersofsurvivorstothe
total number of mice challenged. The challenge strains are indicated above each graph. The challenge doses were 8  108 CFU of O157:H7 strain EDL933 (A),
8  108 CFU of strain EDL933 stx1 (B), 5  108 CFU of strain 86-24 (C), and 9  108 CFU of strain E345 (D).
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sonickillingandbactericidalactivityandprotectedinfantmicein
a lethal GI infection model. Antibodies to both PNAG and Stx
were needed for infant mouse protection against O157 STEC.
These antibodies also mediated killing and protection against the
Stx2-producingEAECO104:H4strainthatcausedtherecentHUS
outbreak centered in Germany (3, 7) but with this strain, mice
were protected with three doses of antibody to PNAG alone. Col-
lectively, our observations suggest that vaccination against both
PNAG and Stx, using a construct such as 9GlcNH2 conjugated to
Stx would be useful against a broad range of STEC serogroups.
PNAG-based vaccines have already been shown to have the
potential to induce full or partial protection against a large range
ofmicrobialpathogens(24,25);ourdemonstrationherethatthey
can contribute to immunity to STEC, potent pathogens conﬁned
to the GI tract, extends the range of microbes and host tissues
wherein these vaccines might contribute to protective efﬁcacy.
Additionally, we demonstrated that PNAG is required for E. coli
O157 virulence in the orogastric infant mouse model of STEC
lethality.TheseﬁndingssuggestthatadditionalPNAG-producing
GI pathogens such as Salmonella enterica and Listeria monocyto-
genes (25) might also be targeted by vaccination against PNAG.
Investigational vaccines to Stx-producing enteric pathogens
target the toxins themselves and often an additional component
suchastheLPSO157antigen,adherencefactors,orotherbacterial
antigens (16, 17). In some experimental mouse infection models,
immunitytoStxaloneissufﬁcientforprotectionagainstE.coliGI
infection (17). Numerous studies to decrease carriage of E. coli
O157infarmanimalshaveshowneffectsfollowingimmunization
with a variety of antigens (14). Whether Stx and other antigens
targeted by these vaccine strategies would be applicable to human
immunity to E. coli O157 is not established, although clinical use
ofMAbstoStxtopreventHUSinchildrenhasbeeninitiated(14).
Our ﬁndings do indicate that augmenting immunity to Stx with
immunitytoPNAGmighthavethepotentialtoreducediarrheaor
shedding of STEC in either animals or humans.
Immunity to pathogens conﬁned to the GI tract requires that
immune effectors such as antibodies, complement, and phago-
cytes gain access to the infecting organisms. While mucosal IgA is
often evoked as a main mediator of this immunity, there is little
substantiveevidenceinhumanslinkingIgAlevelstoimmunityto
GI pathogens that is independent of the presence of concomitant
serum IgM or IgG antibody to the pathogen (32). Furthermore,
the observation that only about 10% of IgA-deﬁcient humans
haveclinicallysigniﬁcantmanifestationoftheirconditionencom-
passingincreasedsusceptibilitytoinfections(32)providesapow-
erful argument that mucosal IgA is not critical for protecting
againstGIpathogens.Incontrast,serumvibriocidalantibodycor-
relates with LPS O-antigen-speciﬁc immunity to Vibrio cholerae
(33), and many examples of successful vaccination by systemic
immunization and/or induction of serum IgG antibodies against
mucosal pathogens such as inﬂuenza virus, poliovirus, and rota-
virus (34), along with reductions in carriage of pathogens that
colonize mucosal surfaces (35), are known.
SerumIgGtransitsontoandofftheGIepitheliumviatheneo-
natal Fc receptor (FcRn) (36) expressed throughout life in hu-
mans on antigen-presenting cells as well as epithelial and endo-
thelialcells.TheFcRncontainsboththemajorhistocompatibility
complex (MHC) class I -2-microglobulin component and the
MHC class II invariant chain, whose synthesis is increased during
FIG 5 Protection against E. coli O157 but not O104 requires both antibody to PNAG and Stx. (A) Five-day-old mice challenged with 5  108 CFU of E. coli
EDL933 by oral gavage were protected following intraperitoneal (i.p.) injection of antibody to 9GlcNH2-Stx1b, but protection could not be achieved with
antibody to a different PNAG oligosaccharide conjugate vaccine, 9GlcNH2-TT. Adding a monoclonal antibody to Stx1 to the PNAG-only antibody (9GlcNH2-
TT) did not achieve protection. (B and C) Protection against E. coli O157 EDL933 stx1 (B) and 86-24 (C) obtained with antibody to 9GlcNH2-Stx1b was lost
afterabsorption(9GlcNH2-Stx1babsorbed)withS.aureusMN8MtoremoveantibodytoPNAG.Similarly,therewasnoprotectionafteradministeringantibody
toPNAGonly(anti-9GlcNH2-TT).Additionofantibodyto9GlcNH2-Stx1babsorbedwithS.aureusMN8MtothePNAG-onlyantiserum9GlcNH2-TTrestored
protective efﬁcacy, indicating that antibodies to both PNAG and Stx are required for protection. Kaplan-Meier survival curves were analyzed by log rank tests.
An asterisk indicates an P value of 0.01 compared to survival in mice given NRS. (D) Survival of infant mice (12 to 14 mice/group; results from two identical
experiments combined) challenged orally after two injections of the indicated antiserum (2X antibody) 16 and 4 h before infection. (E) Survival of infant mice
(5 mice/group) injected with antisera raised to 9GlcNH2-TT given 3 times at 16 h before infection and at 24 and 48 h postinfection. The survival curves were
analyzed by log rank test.
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body to the inﬂamed GI mucosa may be due to increased FcRn
expression or it might also gain access along with additional me-
diators of immunity such as phagocytes, complement, and other
factors via inﬂammation-induced leakage through the disrupted
epitheliumcausedbytheinfectingpathogen.Inthiscontext,con-
cern has been raised about whether antibody to PNAG could dis-
rupt the normal GI microbial ﬂora, and we have addressed this
issueinapriorpublication(25),citingamongmanyotherfactors,
that in the absence of inﬂammation there is unlikely to be an
accumulation of sufﬁcient mediators of PNAG antibody activity
to impact the normal GI microbial constituents. Overall, with
human trials of an IgG1 MAb to PNAG initiated and an
oligosaccharide-basedvaccinebeingdevelopedforclinicaltesting
in humans and economically important animals (24), prospects
are bright that immunity to PNAG can provide a major compo-
nentofhostresistancetoinfectionagainstabroadrangeofpatho-
gens (25), which might need to be augmented by immunization
againstalimitednumberofadditionalmicrobialvirulencefactors
such as Stx.
MATERIALS AND METHODS
Details are provided in Text S1 in the supplemental material.
Bacteria, plasmids, antibodies, and toxins. The bacterial strains and
plasmids used in this study, along with their relevant characteristics and
sources, are listed in Table S1 in the supplemental material.
Detection of PNAG on bacterial surfaces. Confocal scanning laser
microscopywasusedtodetectpoly-N-acetylglucosamine(PNAG)onthe
bacterial surface as described previously (25). Images depicted in the ﬁg-
ures are representative of multiple ﬁelds viewed.
Preparation of the conjugate vaccine. The thiol-derivatized
9GlcNH2-S-S (9GlcNH2 is a synthetic nonamer of nonacetylated PNAG)
oligosaccharidewaspreparedfromsyntheticprecursor(37)aspreviously
described (24).
Antibody production and analysis. Antibodies to puriﬁed 9GlcNH2
conjugatedtotheShigatoxin1bsubunit(9GlcNH2-Stx1b)wereraisedin
New Zealand White rabbits. Binding of antibodies to PNAG and Shiga
toxin (Stx) was analyzed by enzyme-linked immunosorbent assay
(ELISA) as described previously (21).
Antibody-dependent OPK assays. The four key components for op-
sonophagocytic killing (OPK) assays, including cells with phagocytic ac-
tivity, complement, sera, and bacteria were prepared as previously de-
scribed (21) except differentiated HL-60 (American Type Culture
Collection, Manassas, VA) promyelocytic cells were used as the phago-
cytes (38).
Vero cell toxicity assay. The sera were analyzed as described previ-
ously (39) using a Vero cell cytotoxicity assay for the presence of toxin-
neutralizing antibody.
Animal model of lethal STEC infection. Animal experiments com-
pliedwithinstitutionalandfederalguidelinesforanimalcareanduseand
were approved by the Harvard Medical Area Institutional Animal Care
and Use Committee. A moribund/lethal infection model was developed
using 5-day-old CD-1 mice (Charles River Laboratories, Wilmington,
MA). The infant mice were housed with and fed by their mothers; the
mothers were fed a standard diet. Groups of mice were orally challenged
with E. coli strains indicated in the text or the ﬁgure legends in 500 lo f
phosphate-buffered saline (PBS), and survival was monitored for 1 week.
For evaluation of the passive protection conferred by antibodies to
9GlcNH2-Stx1b, 5-day-old mice received 80 l of either normal rabbit
serum (NRS) or antisera to 9GlcNH2-Stx1b injected intraperitoneally
(i.p.). In addition, antibodies to 9GlcNH2-TT (9GlcNH2 conjugated to
tetanus toxoid) (25), monoclonal antibody (MAb) to Stx1b as well as a
combined cocktail of this MAb and antibody to PNAG were evaluated
against strain EDL933 infection.
Serum adsorption and reconstitution experiments. The antiserum
to9GlcNH2-Stx1bwasadsorbedwithheat-killedS.aureusstrainMN8M,
a PNAG overproducer to remove antibody to this antigen or with S. au-
reus MN8ica, which does not produce PNAG, as a control.
Mousesystemicinfectionmodel.Apreviouslydescribedadultmouse
systemic infection model (40) was used to investigate passive protection
provided by antibodies to 9GlcNH2-Stx1b against a non-Stx-producing
E. coli strain.
Statistical analysis. Kaplan-Meier survival cures were analyzed by a
log rank test incorporating Bonferroni’s correction for multiple compar-
isons. Pairwise comparisons of bacterial tissue burdens and overall sur-
vival between immune and control groups were evaluated using a non-
parametricunpairedttestandFisher’sexacttest,respectively.Pvaluesfor
thelatteranalysesweredeterminedfromone-sidedtests,aspreviousdata
and common sense indicated that the effect of the immune serum could
go in only one direction, we could predict ahead of time that mice receiv-
ing nonimmune sera will have the higher tissue bacterial burdens before
wecollectedanydataandifthemicereceivingtheimmuneserahadended
up with the higher tissue bacterial levels, we would have attributed that
difference to chance and called the difference “not statistically signiﬁ-
cant.”
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